Objective Patients presenting with acute coronary syndrome (ACS) are treated with dual
antiplatelet agents, including aspirin and clopidogrel, to prevent mortality and recurrent …

OBJECTIVES: An increasing number of patients are referred for coronary artery bypass graft
surgery while treated with clopidogrel. This agent inhibits the platelet P2Y12 adenosine-5 …

Objective In this 8 years' follow-up study, we evaluated the long-term outcomes of the
addition of clopidogrel to aspirin during the first year after coronary artery bypass grafting …

Background Clopidogrel use post coronary artery bypass grafting (CABG) has become more
popular under the assumption that it improves graft patency. The purpose of this sub …

Aims Thrombotic complications after percutaneous coronary intervention procedures have
decreased in past years mainly due to the use of clopidogrel antiplatelet therapy. However …

Optimal antiplatelet therapy after coronary artery bypass graft (CABG) surgery remains
controversial. This study evaluated the role of dual antiplatelet therapy using aspirin and …

INTRODUCTION: Clopidogrel treatment is associated with a reduction in thrombotic
complications in coronary stent placement, improved outcome after acute coronary …

Antiplatelet therapy has been demonstrated to reduce the risk of cardiac events in patients
presenting with acute coronary syndrome, yet all effective therapies also increase the risk of …

Aims Aspirin combined with clopidogrel is the treatment of choice for acute coronary
syndromes. Although the maintenance of aspirin until surgery does not affect postoperative …

Objectives: The purpose of our multicenter study was to examine the impact of pre-operative
administration of clopidogrel on reoperation rates, incidence of life-threatening bleeding …